ver
last
two
decad
nucleic
acid
emerg
versatil
therapeut
agent
due
abil
target
interfer
flow
genet
inform
dna
protein
promis
nucleic
acid
includ
antisens
oligonucleotid
small
interf
rna
sirna
aptam
ribozym
demonstr
high
structur
divers
express
mani
enzymat
activ
abil
influenc
cell
metabol
bedi
et
al
inde
dnarna
oligonucleotid
current
use
alter
gene
express
sever
differ
approach
sirna
molecul
select
degrad
messeng
rna
mrna
cholesterolconjug
singlestrand
rna
analogu
term
antagomir
block
microrna
antisens
oligoribonucleotid
either
modul
altern
splice
alter
gene
express
pattern
decoy
oligodeoxynucleotid
odn
inhibit
bind
transcript
action
sever
transcript
factor
synthet
odn
contain
one
cpg
stimul
immun
system
triplexform
oligonucleotid
compos
dna
rna
synthet
base
analog
target
mutagenesi
sazani
kole
krutzfeldt
et
al
castanotto
rossi
chin
glazer
vollmer
krieg
bennett
swayz
soldati
et
al
juliano
et
al
literatur
reveal
antisensemedi
exon
skip
repres
promis
treatment
strategi
sever
diseas
via
restor
normal
splice
inde
approach
potenti
applic
cryptic
splice
mutat
bthalassemia
breast
cancer
cystic
fibrosi
switch
altern
splice
isoform
therapeut
potenti
inflammatori
diseas
myoton
dystrophi
antiapoptosi
cancer
induc
exon
inclus
cancer
spinal
muscular
atrophi
correct
read
frame
allow
product
intern
delet
partial
function
protein
duchenn
muscular
dystrophi
dystroph
epidermolysi
bullosa
induct
readingfram
disrupt
achiev
partial
protein
knockdown
exampl
atherosclerosi
cancer
van
roonmom
aartsmaru
idea
behind
splice
therapi
duchenn
muscular
dystrophi
dmd
convert
outoffram
transcript
infram
transcript
code
function
protein
therebi
transform
sever
phenotyp
dmd
milder
form
becker
muscular
dystrophi
van
ommen
et
al
wilton
fletcher
aartsmaru
dougla
wood
fig
notabl
exampl
target
antisensemedi
exon
skip
therapi
alreadi
clinic
trial
stage
progress
therapi
base
nucleic
acid
depend
upon
advanc
chemistri
improv
develop
antisens
oligonucleotid
aon
molecul
backbon
abl
confer
nucleas
resist
without
interf
abil
hybrid
right
target
jarver
et
al
provid
new
carrier
protect
system
administr
lu
et
al
nimesh
et
al
ideal
aon
bind
specif
sequenc
rna
transcript
readili
taken
cell
target
tissu
activ
appropri
intracellular
compart
furthermor
splice
strategi
essenti
aon
molecul
local
nucleu
wherea
sirna
approach
depend
upon
aon
remain
cytoplasm
interf
rna
irna
act
aon
also
need
possess
good
safeti
pharmacokinet
pharmacodynam
profil
well
resist
nucleas
degrad
dougla
wood
due
stabil
nucleolyt
degrad
rel
eas
synthesi
phosphorothio
oligonucleotid
pss
aon
wide
studi
date
vitraven
tm
isi
fomivirsen
first
antisens
drug
approv
us
food
drug
administr
fda
psaon
design
treatment
cytomegalovirusinduc
retin
aid
patient
gearyet
et
al
ps
oligonucleotid
nucleas
resist
confer
replac
nonbridg
oxygen
atom
rna
phosphat
group
sulfur
atom
fig
although
substitut
confer
rnase
h
resist
also
requir
ribos
residu
deleavey
damha
anoth
advantag
phosphorothio
solubl
aris
neg
charg
also
allow
complex
easili
cation
lipid
protein
bennett
swayz
although
readili
conjug
peptid
coval
linkag
dougla
wood
psmodifi
aon
water
solubl
high
proteinbind
capac
prevent
rapid
renal
excret
facilit
uptak
tissu
aon
alter
way
improv
therapeut
prospect
instanc
modif
backbon
yield
thiophosphoramid
analog
stabl
acid
oligonucleotid
unchang
rna
bind
properti
modif
ribos
moieti
aon
give
rise
fig
oligonucleotid
possess
increas
nucleas
resist
targetrna
bind
affin
product
ribos
residu
modif
phosphoramid
oligonucleotid
substitut
amin
group
phosphoramid
nucleas
resist
hybrid
specif
complementari
rna
higher
affin
phosphodiest
phosphorothio
aon
activ
rnase
h
backbon
modif
repres
methylphosphon
one
nonbridg
oxygen
atom
substitut
methyl
group
neutral
charg
fig
schemat
represent
exon
skip
outoffram
delet
exon
duchenn
muscular
dystrophi
dmd
gene
induc
frameshift
mrna
gener
prematur
stop
codon
target
exon
antisens
oligonucleotid
aon
hide
splice
machineri
lead
skip
refram
partial
restor
protein
function
methylphosphon
high
nucleas
resist
abl
activ
rnase
h
moreov
high
methylphosphon
content
oligom
decreas
solubl
affin
target
rna
anoth
common
class
aon
morpholino
phosphorodiamid
oligom
pmo
nonion
backbon
physiolog
ph
ribos
sugar
replac
morpholin
moieti
phosphorodiest
intersubunit
bond
phosphorodiamid
linkag
fig
pmo
chargeneutr
refractori
biolog
degrad
amantana
iversen
morpholino
activ
rnase
h
block
protein
translat
mechan
splice
moreov
nonion
properti
pmo
prevent
potenti
nonspecif
interact
cellular
compon
possibl
conjug
pmo
differ
deliveri
system
cell
penetr
peptid
cpp
addit
modifi
chemistri
pmo
provid
excel
resist
nucleas
proteas
activ
amantana
iversen
pan
clawson
bennett
swayz
dougla
wood
peptid
nucleic
acid
pna
anoth
class
neutral
charg
aon
resist
nucleas
proteas
degrad
possess
backbon
repeat
n
glycin
unit
nucleobas
bound
via
carbonyl
linkag
nielsen
fig
pna
abl
hybrid
dna
rna
mechan
base
translat
inhibit
splice
modul
howev
due
lack
charg
pna
molecul
character
low
solubl
weak
cellular
uptak
reason
pna
conjug
short
peptid
modifi
bear
charg
amino
acid
backbon
oligonucleotid
type
deliv
tissu
cell
order
reach
target
transcript
carri
function
nake
oligonucleotid
featur
phosphorothio
linkag
sugar
modif
enter
hepatocyt
kidney
cell
effici
vivo
howev
bioavail
limit
poor
cell
traffick
endosom
entrap
et
al
prompt
rigor
search
new
deliveri
system
capabl
deliv
nucleic
acid
target
cell
optim
deliveri
system
need
target
cell
specif
control
term
drug
releas
abl
protect
nucleic
acid
bedi
et
al
liposom
polym
cellpenetr
peptid
propos
vehicl
clinic
applic
plagu
lack
cell
specif
mention
difficulti
control
drug
releas
research
recent
begun
focu
nanotechnolog
potenti
nonvir
deliveri
system
vehicl
could
deliv
varieti
drug
macromolecul
like
protein
oligonucleotid
plasmid
dna
via
variou
administr
rout
includ
intraven
oral
intramuscular
pulmonari
intranas
ocular
rectal
intraperiton
lamprecht
et
al
de
rieux
et
al
diebold
calong
cherif
et
al
zhao
castranova
fig
main
devic
use
nanomedicin
raghuwanshi
et
al
schairer
et
al
wanakul
et
al
wang
et
al
nanomed
agent
class
accord
physicochem
featur
size
affect
use
liposom
nm
nanoparticl
nm
block
copolym
micel
nm
gold
nanoparticl
nm
nanos
drug
crystal
nm
develop
duncan
gaspar
fig
howev
use
success
certain
issu
still
remain
address
difficulti
stabl
nucleic
aciddrug
nanocomplex
format
identif
suitabl
administr
rout
abilityin
system
deliveri
reliabl
tissu
target
limit
intracellular
uptak
final
effect
regul
gene
express
stage
sever
synthet
lipidand
polymerbas
nanocarri
synthes
test
nucleic
acid
deliveri
system
nanoparticl
better
safeti
profil
viral
vector
adapt
nucleic
acid
small
molecul
drug
readili
lend
chemic
modif
function
li
et
al
us
fda
approv
lupron
depot
first
parenter
sustainedreleas
formul
base
biodegrad
poli
llactid
pla
copolym
poli
ethylen
glycol
peg
poli
llactidecoglycolid
plga
name
genexolpm
formul
paclitaxel
nanoparticl
np
use
treat
breast
cancer
phase
clinic
trial
unit
state
parenter
plga
nanoparticl
use
carrier
variou
applic
vaccin
cancer
therapi
treatment
cerebr
disord
danhier
et
al
exampl
woodrow
cowork
obtain
effici
sustain
gene
silenc
mous
femal
reproduct
tract
sirna
load
plga
np
woodrow
et
al
plga
nanoparticl
number
intrins
drawback
inde
consid
weak
drugdeliveri
system
intraven
administr
undergo
rapid
clearanc
reach
site
action
moreov
plga
np
abl
discrimin
differ
cell
type
sah
et
al
howev
research
shown
surfac
modif
improv
function
panyam
colleagu
instanc
demonstr
introduc
aminerich
cation
polym
poli
ethylen
imin
pei
plga
matrix
improv
oligonucleotid
encapsul
well
sirna
retent
releas
due
fact
pei
hydrophil
plga
henc
readili
dissolv
aqueou
buffer
pei
also
contain
number
amino
group
proton
physiolog
ph
therebi
confer
potenti
combin
neg
charg
nucleic
acid
effect
prevent
biodegrad
reach
target
cell
addit
accord
proton
spong
effect
hypothesi
akinc
et
al
pei
assist
cargo
escap
endosom
cytoplasm
incorpor
pei
plga
nanoparticl
also
affect
cellular
uptak
increas
cellular
accumul
furthermor
test
two
differ
cell
cultur
model
suggest
sirnaload
plgapei
np
efficaci
reduc
gene
express
patil
panyam
also
possibl
deliv
drugnucl
acid
combin
directli
encapsul
type
agent
biodegrad
polyest
particl
instanc
panyam
et
al
describ
simultan
deliveri
paclitaxel
pglycoprotein
sirna
use
plgapei
nanoparticl
patil
et
al
cytotox
pei
major
limit
overcom
use
low
concentr
pei
patil
panyam
yang
et
al
pei
cation
toxic
also
minim
conjug
peg
yield
differ
set
pegpei
copolym
character
differ
size
molecul
coupl
pei
nonion
peg
polym
coat
provid
dimension
shield
improv
biolog
stabil
transfect
complex
prolong
circul
time
via
reduc
nonspecif
protein
bind
serum
neu
et
al
coat
np
surfac
hydrophil
polym
peg
known
enhanc
colloid
stabil
extracellular
environ
reduc
recognit
mononuclear
phagocyt
system
raemdonck
et
al
inde
peg
coat
provid
plga
nanoparticl
hydrophil
corona
fig
therebi
overcom
signific
obstacl
use
nake
plga
np
name
hydrophob
inde
nanoparticl
neg
surfac
charg
vulner
opson
rapid
elimin
blood
intraven
administr
sheng
et
al
pegyl
therefor
improv
aqueou
solubl
stabil
reduc
intermolecular
aggreg
immunogen
prolong
system
circul
time
sah
et
al
liang
cowork
success
use
nanoscal
particl
form
pegpei
sirna
silenc
express
nogo
receptor
central
nervou
system
cn
np
demonstr
high
efficaci
low
toxic
make
ideal
candid
mediat
gene
express
cn
liang
et
al
moreov
william
colleagu
show
dystrophin
express
significantli
increas
mdx
mice
given
intramuscular
inject
conjug
complex
set
pegpei
copolym
contain
kda
pei
either
da
kda
peg
abl
bind
high
affin
form
stabl
complex
low
surfac
charg
enhanc
biocompat
cellular
uptak
peipeg
copolym
also
coval
conjug
nanogold
ng
adsorb
colloid
gold
cg
signific
differ
found
dystrophin
express
nonfunction
copolym
result
formul
pegpei
copolym
function
cellpenetr
peptid
tat
transactiv
transcript
cg
tat
cg
also
yield
promis
result
highest
level
dystrophin
found
muscl
mdx
mice
intramuscularli
inject
conjug
differ
pegpei
complex
function
tat
respect
mdx
treat
alon
adsorpt
cg
either
pegpei
tatpegpei
copolym
fail
increas
dystrophin
express
altern
system
effici
deliveri
aon
sirna
molecul
nonion
controlledreleas
polym
vesicl
polymersom
polymersom
character
aqueou
lumen
suitabl
load
drug
releas
occur
either
oxidationsensit
hydrolysissensit
copolym
amphiphil
polymersom
circul
vivo
longer
lipid
vesicl
degrad
produc
surfact
induc
endolysosom
releas
kim
et
al
fig
novel
class
molecul
term
lipid
nanoparticl
lnp
develop
deliv
short
rna
mammalian
cell
vitro
vivo
lnp
contain
ioniz
amino
lipid
selfassembl
nanoparticl
nm
mix
polyanion
oligonucleotid
play
dual
role
drug
deliveri
process
electrostat
interact
lnp
polyanion
nucleic
acid
promot
encapsul
sirna
abl
escap
endosom
compart
access
cell
cytoplasm
follow
endocytosi
lnp
target
cell
jayaraman
et
al
lipid
nanoparticl
lnp
differ
composit
cation
lipid
peg
cholesterol
use
deliv
luciferas
sirna
liver
via
system
intraven
administr
mice
tao
et
al
anoth
class
lipidlik
deliveri
molecul
term
lipidoid
also
use
effici
deliv
immunostimulatori
rna
isrna
tolllik
receptorexpress
cell
subcutan
inject
stimul
innat
adapt
immun
respons
librari
lipidoid
synthes
conjug
isrna
shown
induc
typei
interferon
activ
human
peripher
blood
mononuclear
cell
nguyen
et
al
vector
develop
enhanc
cell
deliveri
oligonucleotid
sirna
cppsshort
cation
amphipath
peptid
capac
enter
cell
deliv
differ
molecul
across
cell
membran
exampl
natur
cpp
tat
domain
penetr
domain
drosophila
antennapedia
dupont
et
al
cpp
contain
cation
amino
acid
multipl
arginin
strongli
enhanc
aon
deliveri
due
abil
carri
associ
cargo
across
plasma
endosom
membran
yin
cowork
report
promis
new
peptid
pmo
name
abl
restor
high
level
dystrophin
synthesi
muscl
mdx
mice
singl
mgkg
administr
yin
et
al
ezzat
collabor
demonstr
new
cpp
pepfect
bind
sirna
noncoval
interact
abl
induc
effici
rna
interfer
respons
differ
cell
type
ezzat
et
al
chitosanpluron
poli
isobutyl
cyanoacryl
pibca
nanoparticl
obtain
emuls
polymer
also
attract
carrier
vivo
deliveri
oligonucleotid
efficaci
intraven
inject
sirnapibca
complex
test
mice
papillari
thyroid
carcinoma
result
signific
reduct
tumor
growth
de
martimprey
et
al
zandanel
vauthier
recent
propos
model
investig
pibca
np
deliv
sirna
biolog
target
cell
cultur
vivo
zandanel
vauthier
incorpor
fluoresc
probe
pibca
nanoparticl
coval
linkag
without
modifi
surfac
properti
latter
anoth
focu
recent
research
inorgan
nanobiomateri
sinc
compar
organ
materi
show
high
thermalchem
stabil
resist
corros
physiolog
condit
moreov
character
good
biocompat
low
degrad
rate
silica
one
biocompat
materi
use
endogen
substanc
present
mainli
bone
use
commerci
excipi
sever
drug
addit
silica
use
synthes
one
recent
develop
organicinorgan
hybrid
nanomateri
combin
advantag
organ
inorgan
materi
thank
high
poros
biocompat
mesopor
silica
nanoparticl
msn
system
synthes
coassembl
organ
structur
direct
agent
inorgan
silic
speci
provid
effici
drugdeliveri
sirna
na
et
al
msn
pore
demonstr
highli
effici
specif
without
signific
cytotox
vitro
vivo
studi
howev
especi
therapeut
purpos
degrad
behavior
np
still
requir
clarif
refin
chen
et
al
silver
also
use
synthesi
new
type
nanoparticl
silver
nanoparticl
decor
thioltermin
photolabil
dna
oligonucleotid
show
enhanc
stabil
resist
enzymat
degrad
greater
cellular
uptak
photoactiv
control
restor
therapeut
activ
antisens
deliveri
compar
nake
nucleic
acid
brown
et
al
oligodeoxynucleotid
also
effici
deliv
cell
calcium
phosphat
cp
base
carrier
develop
hou
cowork
spheric
porou
odncp
nanoparticl
diamet
nm
use
case
prepar
facil
microemuls
approach
hou
et
al
fabric
microand
nanoparticl
defin
featur
shape
size
surfac
charg
stiff
chemic
composit
also
perform
highresolut
mold
technolog
known
particl
replic
nonwet
templat
techniqu
enabl
synthesi
particl
variou
biocompat
biodegrad
materi
peg
protein
plga
wide
use
creat
hydrogel
nanogel
nanoparticl
diamet
nm
length
rang
nm
studi
deliveri
system
cellular
transfect
sirna
dunn
et
al
kersey
et
al
nanomateri
report
two
section
briefli
describ
tabl
duchenn
muscular
dystrophi
one
common
inherit
neuromuscular
disord
caus
mutat
dmd
gene
encod
protein
dystrophin
lie
chromosom
locu
emeri
dystrophin
mutat
usual
seen
dmd
patient
caus
loss
ctermin
domain
dystrophin
result
nonfunct
protein
howev
mutat
involv
part
central
rod
domain
may
still
allow
product
function
dystrophin
protein
seen
milder
condit
becker
muscular
dystrophi
bmd
kingston
et
al
less
sever
phenotyp
form
diseas
provid
basi
dmd
treatment
splice
modul
dougla
wood
delet
dmd
gene
exon
caus
shift
open
read
frame
splice
transcript
frameshift
lead
incorpor
prematur
stop
codon
downstream
region
transcript
produc
protein
nonfunct
possibl
unstabl
moreov
prematur
termin
codon
middl
transcript
could
lead
degrad
transcript
via
activ
nonsensemedi
mrnadecay
cellular
pathway
buvoli
et
al
contrast
mainten
normal
open
read
frame
lead
function
dystrophin
bmd
phenotyp
monaco
et
al
convers
outoffram
transcript
infram
transcript
code
function
protein
goal
antisensemedi
exon
skip
strategi
dmd
aartsmaru
van
ommen
two
clinic
trial
end
ongo
european
compani
prosensa
therapeut
glaxosmithklin
gsk
explor
chemistri
drisapersen
avibiopharma
sarepta
investig
chemistri
pmo
eteplirsen
prosensa
publish
initi
result
clinic
trial
conduct
netherland
four
dmd
boy
receiv
singl
dose
mg
inject
tibiali
anterior
muscl
specif
skip
exon
percentag
rang
dystrophinposit
myofib
detect
van
deutekom
et
al
pmo
chemistri
use
similar
studi
unit
kingdom
seven
dmd
boy
receiv
either
mg
one
two
extensor
digitorum
brevi
muscl
exon
skip
observ
muscl
treat
dose
howev
dystrophin
restor
detect
receiv
higher
dose
specif
fiber
encouragingli
signific
side
effect
note
either
trial
cirak
et
al
aon
chemistri
produc
dystrophin
rescu
patient
albeit
variou
degre
intens
skip
percentag
actual
two
aon
chemistri
subject
system
clinic
trial
term
http
term
dmd
pg
clinic
trial
phase
aon
need
test
vivo
anim
model
diseas
studi
provid
much
preclin
evid
potenti
exon
skippingbas
dmd
therapi
wide
studi
use
anim
dmd
model
date
mdx
xchromosomelink
muscular
dystrophi
mous
carri
spontan
mutat
identifi
mous
line
bulfield
et
al
mutat
singl
nucleotid
substitut
exon
result
prematur
stop
codon
dystrophin
gene
caus
absenc
protein
muscl
even
though
rare
revert
myofib
may
present
sicinski
et
al
hoffman
et
al
human
dmd
lead
earli
loss
muscl
function
dystrophinnul
mice
show
mild
symptom
old
age
chamberlain
et
al
probabl
due
presenc
utrophin
autosom
homologu
dystrophin
anim
nakagaki
camilli
henc
obtain
phenotyp
model
closer
human
diseas
utrophindystrophin
doubleknockout
mice
creat
show
sever
phenotyp
mani
sign
human
dystrophi
ie
sever
muscl
weak
reduc
lifespan
cardiomyopathi
growth
retard
durbeej
campbel
vainzof
et
al
sever
dog
breed
also
propos
dystrophi
model
although
character
current
studi
mostus
dog
coloni
beagl
corgi
golden
retriev
muscular
dystrophi
model
grmd
duan
beagl
grmd
model
share
mutat
splice
site
mutat
intron
although
latter
wide
studi
smith
et
al
mutat
induc
exon
skip
format
prematur
stop
codon
exon
result
absenc
dystrophin
accompani
sever
phenotyp
sever
mutat
canin
dmd
model
also
identifi
duan
kornegay
et
al
remain
costli
requir
doubl
exon
skip
make
mdx
mous
prefer
model
first
exon
skip
approach
test
mdx
mice
use
phosphorothio
aon
result
effici
local
restor
dystrophin
lu
et
al
effici
boost
studi
use
pmo
peptidetag
pmo
nonpeptid
polymertag
pmo
wu
et
al
goyenval
et
al
result
studi
shown
muscular
dystrophi
amelior
mous
model
repeat
intravascular
intraperiton
aon
inject
moreov
endur
dystrophin
express
achiev
combin
aonmedi
exon
skip
adenoassoci
viru
aav
gene
transfer
goyenval
et
al
aon
chemistri
use
improv
dystrophin
restor
mdx
mice
phosphorothio
falzarano
passarelli
ferlini
rna
moep
aon
geari
et
al
inde
yang
cowork
demonstr
moe
aon
induc
efficaci
exon
skip
vitro
mdx
mice
local
intramuscular
inject
interestingli
significantli
higher
level
dystrophin
express
seen
mice
treat
way
indic
could
promis
effici
exon
skip
strategi
dmd
yang
et
al
unsurprisingli
therefor
mani
anim
model
studi
focus
identif
new
deliveri
system
aon
molecul
order
improv
effici
safeti
strategi
recent
year
mani
aon
synthet
molecul
employ
aonmedi
molecular
therapi
order
use
drug
applic
aon
design
must
allow
molecul
enter
cell
nucleu
specif
hybrid
target
rna
biodistribut
target
organ
jarver
et
al
aon
intak
also
dosedepend
rais
concern
increas
dose
therapeut
rang
could
major
side
effect
especi
term
renal
overload
henri
et
al
furthermor
nake
aon
intern
poorli
cell
tend
local
endosomeslysosom
ineffect
nonetheless
aon
uptak
occur
activ
transport
depend
adsorpt
endocytosi
fluid
phase
pinocytosi
mean
aon
intern
might
achiev
interact
membranebound
receptor
de
diesbach
et
al
variou
techniqu
improv
cellular
uptak
test
success
date
term
efficaci
coupl
aon
basic
peptid
membran
transloc
properti
particular
system
deliveri
morpholino
oligom
conjug
cellpenetr
peptid
pip
contain
stretch
arginin
yield
excel
result
bring
consider
dystrophin
rescu
even
heart
normal
poorli
target
aon
yin
et
al
although
aonconjug
transduc
peptid
promis
concern
pip
toxic
persist
due
abil
activ
mani
signal
pathway
juliano
et
al
order
enhanc
vivo
aon
applic
increas
stabil
enabl
use
lower
concentr
sever
vector
chaperon
develop
among
chimer
small
nuclear
rna
snrna
molecul
snrna
use
aav
retroviru
shown
effici
induc
exon
skip
mendel
et
al
number
transport
liposom
cation
polym
molecular
spong
mechan
test
variou
result
dia
stein
particular
two
new
class
nonvir
biocompat
nanoparticl
call
recent
shown
bind
deliv
aon
mdx
mice
treat
intraperiton
ip
administr
rimessi
et
al
ferlini
et
al
nanoparticl
made
polymethyl
methacryl
pmma
core
surround
shell
whose
cation
carri
group
ideal
aon
bind
shown
mitig
desorpt
instabl
issu
fig
follow
falzarano
passarelli
ferlini
previou
report
anion
cation
pmmabas
nanoparticl
feasibl
deliveri
system
protein
dna
vaccin
caputo
et
al
nanoparticl
abl
convey
oligoribonucleotid
good
effici
load
valu
mg
aonmg
np
aon
modifi
rna
contain
fulllength
phosphorothio
backbon
design
boundari
sequenc
exon
intron
mous
dystrophin
gene
gebski
et
al
quaternari
ammonium
group
nanoparticl
surfac
matrix
facilit
strong
lipophil
interact
hydrophob
oligoribonucleotid
rimessi
et
al
rimessi
cowork
show
administr
aon
conjug
abl
restor
dystrophin
protein
express
skelet
muscl
increas
dystrophin
transcript
protein
express
biodistribut
studi
also
demonstr
nanoparticl
abound
variou
tissu
organ
mdx
mice
treat
via
ip
inject
fluoresc
aonfre
np
electron
microscop
nanoparticl
appear
electrontransluc
round
structur
expect
size
nm
fig
found
insid
cytoplasm
macrophag
lymphat
vessel
endotheli
cell
blood
vessel
tabl
summar
schedul
ip
inject
test
approach
thank
np
bodywid
distribut
protein
synthesi
restor
approach
could
consid
effect
mean
deliv
aon
dmd
therapi
howev
nanoparticl
biodegrad
slowli
potenti
lead
accumul
potenti
advers
effect
moreov
np
form
small
aggreg
would
therefor
suitabl
intraven
administr
rimessi
et
al
anoth
class
polymer
cation
coreshel
np
np
compos
pmma
core
random
copolym
shell
form
unit
deriv
nisopropylacrylamid
nipam
reactiv
methacrylatebear
cation
group
fig
electron
microscop
analysi
expect
diamet
nm
fig
nanoparticl
nontox
vitro
demonstr
great
effici
adsorb
aon
load
valu
mg
aon
per
mg
np
figur
show
ip
inject
nake
aon
given
mdx
mice
ferlini
cowork
show
immunohistochem
quantif
analysi
complex
induc
dystrophin
restor
skelet
muscl
heart
dystrophin
restor
achiev
use
mg
aonkg
anim
suggest
lower
dose
aon
administ
longer
period
might
suffici
induc
detect
dystrophin
restor
ferlini
et
al
studi
bassi
collabor
test
protect
effect
nanoparticl
aon
molecul
month
end
low
dosag
treatment
show
effect
dystrophin
express
persist
long
suspens
treatment
demonstr
restor
dystrophin
correctli
local
sarcolemm
membran
muscl
fiber
western
blot
analysi
reveal
protein
exact
molecular
weight
treat
mice
undetect
nakedaon
treat
mice
bassi
et
al
taken
whole
find
clearli
indic
potenti
nanoparticl
nontox
deliveri
vector
aon
protect
effect
aon
molecul
particularli
appeal
characterist
inde
np
could
reduc
dose
aon
requir
therebi
reduc
possibl
side
effect
durat
administr
schedul
howev
clear
need
synthes
test
novel
np
differ
bind
capac
base
coval
electrostat
charg
higher
stabil
aon
order
increas
efficaci
effect
term
dystrophin
rescu
drug
deliveri
certainli
key
factor
optim
treatment
efficaci
effici
may
enabl
us
reduc
undesir
offtarget
effect
side
effect
dose
requir
antisens
oligoribonucleotid
aon
shown
great
potenti
treatment
variou
diseas
duchenn
muscular
dystrophi
nevertheless
select
fig
inject
schedul
upper
panel
immunohistochem
analysi
mdx
skelet
muscl
first
lower
left
panel
second
lower
right
sacrific
muscl
section
mm
label
polyclon
antidystrophin
antibodi
reveal
antirabbit
secondari
antibodi
green
signal
inj
inject
ip
intraperiton
falzarano
passarelli
ferlini
deliveri
target
tissu
striat
muscl
prove
challeng
striat
muscl
compris
skelet
cardiac
muscl
proven
difficult
target
high
level
organ
sarcolemma
membran
represent
sinc
percentag
bodi
weight
muscl
men
women
aon
therefor
improv
target
auspici
muscl
avoid
overload
organ
especi
kidney
dose
regimen
sinc
current
trial
use
quit
high
dose
molecul
signific
progress
made
recent
year
nanoscal
drug
deliveri
system
employ
divers
chemic
formul
facilit
rate
drug
deliveri
improv
pharmacokinet
biocompat
nanomateri
mainli
use
drugdeliveri
system
natur
element
use
produc
advanc
biomateri
great
import
medicin
chemistri
requir
face
sever
challeng
relat
nanoparticl
synthesi
conjug
np
surfac
modif
anoth
key
issu
optim
bind
capac
aon
introduct
variou
reactiv
function
group
surfac
nanomateri
nonetheless
concern
emerg
toxic
pharmacokinet
biocompat
nanomateri
indic
need
rigor
vivo
experi
anim
model
also
novel
nanomateri
practic
applic
clinic
set
inde
need
defin
pharmacokinet
npdrug
system
administr
especi
biophas
bioavail
pharmacokinet
studi
biodistribut
bioavail
np
still
limit
low
label
system
field
also
need
extens
research
elimin
anoth
crucial
issu
must
fine
explor
order
propos
np
clinic
trial
conclus
nanomateri
certainli
appeal
drug
vehicl
show
great
promis
regard
futur
studi
aim
address
issu
well
identifi
novel
biocompat
even
better
biodegrad
compound
doubtless
improv
clinic
applic
deliveri
vehicl
novel
deliveri
system
also
expect
open
entic
new
avenu
term
administr
rout
move
toward
noninvas
skin
oral
administr
progress
area
made
date
indic
real
revolut
rna
therapi
particular
refer
dmd
around
corner
